Randomized trial demonstrates enhanced obesity management through AI, suggesting promising implications for patient care.
Obesity is a chronic, complex disease with excessive fat accumulation conferring increased risk of metabolic disease, cardiovascular disease and other disorders. Its rising global burden has implications on health and economic costs with the need for innovative, sustainable solutions to its management. The conventional interventions of lifestyle modification and pharmacotherapy have been limited by their long-term effectiveness. Artificial Intelligence (AI) is the game-changer in the management of obesity with the potential of predictive modeling, machine learning (ML) algorithms and digital health solutions for maximizing early detection, customized care and continuous monitoring. AI-enabled tools such as chatbots, wearable devices and remote monitoring devices enable real-time intervention, enhance patient compliance and optimize clinical workflows. Additionally, AI-based analytics as part of electronic health records provide risk stratification, allowing the identification of high-risk patients and targeted intervention. Apart from the clinical intervention, AI enables medical education, research and optimization of healthcare systems, laying the ground for a transition from reactive to proactive management of obesity. This review comprehensively deals with the potential of AI in transforming obesity interventions through an analysis of its usage across various domains of healthcare. Additionally, it addresses the limitations and challenges in AI applications such as data privacy, algorithmic bias and the need for multidisciplinary collaborations in ensuring equitable and ethical deployment. Despite the limitations, AI is poised to revolutionize obesity care by enhancing accessibility, customization and long-term outcomes. The use of AI with digital health interventions not only maximizes the benefits to individual patients but also enables prevention of obesity at a population level with a scalable and cost-effective model.
No takes yet. Share an insight, caveat, or question.
Tanushree Bhattacharjee2 Prasan Das1* (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: